(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 August 2002 (29.08.2002)

PCT

(10) International Publication Number
WO 02/066484 A1

(51) International Patent Classification[7]: C07D 498/04, 261/20, A61K 31/495, A61P 25/00

(21) International Application Number: PCT/EP02/01567

(22) International Filing Date: 13 February 2002 (13.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01200611.0 21 February 2001 (21.02.2001) EP
01201264.7 5 April 2001 (05.04.2001) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ANDRÉS-GIL, José, Ignacio** [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid (ES). **FERNÁNDEZ-GADEA, Francisco, Javier** [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid (ES). **ALCÁZAR-VACA, Manuel, Jesús** [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid (ES). **CID-NUÑEZ, José, Maria** [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid (ES). **PASTOR-FERNANDEZ, Joaquin** [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid (ES). **MEGENS, Antonius, Adrianus, Hendrikus, Petrus** [NL/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **HEYLEN, Godelieve, Irma, Christine, Maria** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LANGLOIS, Xavier, Jean, Michel** [FR/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BAKKER, Margaretha, Henrica, Maria** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **STECKLER, Thomas, Horst, Wolfgang** [DE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).


(74) Agent: **VAN BORM, Werner**; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,

*[Continued on next page]*

(54) Title: ISOXAZOLINE DERIVATIVES AS ANTI-DEPRESSANTS




(I)

(57) Abstract: The invention concerns substituted isoxazolines derivatives according to Formula (I): wherein X = CH?2#191, N-$R_7$, S or O, $R_1$, $R_2$ and $R_3$ are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S ; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonine (5-HT) reuptake inhibitor activity in combination with additional α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compounds according to the invention are also suitable for treating patients with anxiety disorders and disorders of body weight. The invention also relates to novel combination of substituted isoxazolines derivatives having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

WO 02/066484 A1

GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**
— *with international search report*